Related Experiment Videos
Organ preservation in rectal cancer
V Valentini1, L Ziccarelli, M E Rosetto
1Cattedra di Radioterapia, Università Cattolica del S. Cuore, Policlinico A. Gemelli, Roma, Italy.
Rays
|July 1, 1997
Summary
Combined therapies effectively preserve sphincter function in distal rectal cancer patients. Ongoing trials refine patient selection and optimal treatment strategies for improved outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Distal rectal cancer treatment prioritizes sphincter preservation.
- Three clinical trials investigated different therapeutic approaches for this goal.
Purpose of the Study:
- To evaluate the efficacy of combined modality therapies in achieving sphincter preservation for distal rectal cancer.
- To assess treatment toxicity and functional outcomes in patients undergoing these novel treatment regimens.
Main Methods:
- Trial 1: T2 patients received local excision and 45 Gy external beam radiotherapy (ERT).
- Trial 2 (FUMIR): T3 patients received mitomycin C, 5-fluorouracil (5FU), and 38 Gy ERT.
- Trial 3 (PLAFUR): T3 patients received cisplatin, 5FU, and 50.4 Gy ERT.
Main Results:
- Sphincter preservation rates were 86% (T2), 66% (T3 FUMIR), and 73.7% (T3 PLAFUR).
- Excellent or good sphincter function was reported in >86% of patients across all trials.
- Acute and late toxicities were generally low, with no observed late toxicity.
Conclusions:
- Combined modality therapies demonstrate significant potential for sphincter preservation in distal rectal cancer.
- Further research is ongoing to identify optimal patient candidates and treatment combinations.